AnthonyEliasMD

Oncology • Aurora, CO

Breast Cancer, Sarcoma

Professor of Medicine, University Colorado

Join to view full profile

Dr. Elias is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Elias' full profile

Already have an account?

Office
12605 E 16th Ave
Aurora, CO 80045
Phone+1 720-848-0000

Summary

Dr. Anthony Elias is an oncologist in Aurora, CO and is affiliated with multiple hospitals in the area, including University of Colorado Hospital and the UCHealth system. He received his medical degree from NYU School of Medicine and has been in practice 37 years. He specializes in breast cancer and sarcoma and is experienced in breast cancer, sarcomas, and general medical oncology.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1983 - 1987
Johns Hopkins UniversityResidency, Internal Medicine, 1980 - 1983
New York University School of MedicineClass of 1980

Certifications & Licensure

CO State Medical License 2000 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly
America's Top Doctors for Cancer Castle Connolly, 2009-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
Recruiting
Phase 2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer Start of enrollment: 2010 Dec 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Phase II Trial for Large ER-Negative Breast Cancers Start of enrollment: 2003 Mar 05
Completed
Phase 2
Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy Start of enrollment: 2013 Apr 02
Completed
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer Start of enrollment: 2017 Jul 06
Completed
Phase 2
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer Start of enrollment: 2017 Sep 21
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.
Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M Bauer
Journal of Immunotherapy and Precision Oncology. 2025-02-01
6 citations
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
2 citations
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda
Nature Medicine. 2024-12-01

Journal Articles

Male Breast Cancer: A Disease Distinct from Female Breast Cancer
Anthony D. Elias, Ayca Gucalp, Breast Cancer Research and Treatment
Efficacy and Tolerability of Trabectedin in Elderly Patients with Sarcoma: Subgroup Analysis from a Phase 3, Randomized Controlled Study of Trabectedin or Dacarbazine ...
A Elias, M Milhem, S Patel, S M Schuetze, M L Hensley, Annals of Oncology

Other

Pathobiology and staging of small cell carcinoma of the lung
Elias A
http://www.uptodate.com/contents/pathobiology-and-staging-of-small-cell-carcinoma-of-the-lung
UpToDate, Wolters Kluwer Health - 2012-05-30

Press Mentions

Grant Means More Access to Cancer Treatment Trials in ColoradoJanuary 17th, 2017
Phase 1 Results Point to Larger Trial of Enzalutamide and Fulvestrant in Breast CancerDecember 7th, 2015
Prostate Cancer Drug Shows Promise in Triple-Negative and Estrogen-Positive Breast CancerDecember 3rd, 2012
Join now to see all